Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.
Brandes AA, Finocchiaro G, Zagonel V, Reni M, Fabi A, Caserta C, Tosoni A, Eoli M, Lombardi G, Clavarezza M, Paccapelo A, Bartolini S, Cirillo L, Agati R, Franceschi E. Brandes AA, et al. Among authors: caserta c. Oncotarget. 2017 Feb 25;8(33):55575-55581. doi: 10.18632/oncotarget.15735. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903444 Free PMC article.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators. Chi KN, et al. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150574 Free article. Clinical Trial.
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J, Aragon-Ching JB, Wang J, Huang B, Laliberte RJ, di Pietro A, Grivas P. Powles T, et al. Among authors: caserta c. J Clin Oncol. 2023 Jul 1;41(19):3486-3492. doi: 10.1200/JCO.22.01792. Epub 2023 Apr 18. J Clin Oncol. 2023. PMID: 37071838 Free PMC article. Clinical Trial.
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E. Brandes AA, et al. Among authors: caserta c. Neuro Oncol. 2016 Sep;18(9):1304-12. doi: 10.1093/neuonc/now035. Epub 2016 Mar 6. Neuro Oncol. 2016. PMID: 26951379 Free PMC article. Clinical Trial.
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G. Verzoni E, et al. Among authors: caserta c. Oncotarget. 2016 Jun 28;7(26):40085-40094. doi: 10.18632/oncotarget.9485. Oncotarget. 2016. PMID: 27223078 Free PMC article.
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
Padovan M, Eoli M, Pellerino A, Rizzato S, Caserta C, Simonelli M, Michiara M, Caccese M, Anghileri E, Cerretti G, Rudà R, Zagonel V, Lombardi G. Padovan M, et al. Among authors: caserta c. Cancers (Basel). 2021 Jun 3;13(11):2773. doi: 10.3390/cancers13112773. Cancers (Basel). 2021. PMID: 34204877 Free PMC article.
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, Franceschi E, Gaviani P, Stasi I, Caserta C, Brugnara S, Lolli I, Bennicelli E, Bini P, Cuccu AS, Scoccianti S, Padovan M, Gori S, Bonetti A, Giordano P, Pellerino A, Gregucci F, Riva N, Cinieri S, Internò V, Santoni M, Pernice G, Dealis C, Stievano L, Paiar F, Magni G, De Salvo GL, Zagonel V, Lombardi G. Caccese M, et al. Among authors: caserta c. ESMO Open. 2024 Apr;9(4):102943. doi: 10.1016/j.esmoop.2024.102943. Epub 2024 Mar 15. ESMO Open. 2024. PMID: 38492275 Free PMC article.
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.
De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg CN. De Giorgi U, et al. Among authors: caserta c. Clin Cancer Res. 2019 Jul 1;25(13):3839-3846. doi: 10.1158/1078-0432.CCR-18-3661. Epub 2019 Apr 9. Clin Cancer Res. 2019. PMID: 30967420 Free article.
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, Massari F, Verzoni E, Cannella A, Maratta MG, Caserta C, Bimbatti D, Deppieri FM, Dessi M, Paolieri F, Riccardi F, Bracarda S, De Giorgi U, Basso U, Tortora G, Procopio G. Iacovelli R, et al. Among authors: caserta c. Clin Genitourin Cancer. 2022 Oct;20(5):498.e1-498.e9. doi: 10.1016/j.clgc.2022.06.006. Epub 2022 Jun 9. Clin Genitourin Cancer. 2022. PMID: 35768316
103 results